Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. [electronic resource]
Producer: 20111115Description: 90ra59 p. digitalISSN:- 1946-6242
- Animals
- Antineoplastic Agents -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Drug Resistance, Neoplasm -- genetics
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride
- Evolution, Molecular
- Female
- Gefitinib
- Genes, erbB-1 -- drug effects
- Humans
- Mice
- Mice, Nude
- Models, Theoretical
- Mutation
- Neoplasm Transplantation
- Protein Kinase Inhibitors -- pharmacology
- Quinazolines -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.